Cell Therapy Bioprocessing Market Size, Share Forecast to 2028

report image

Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Technology, Cell Type); Indication (Cardiovascular Disease (CVD), Oncology, Wound Healing, Orthopedic, Others); End user (Hospitals and Clinics, Diagnostic Centers, Regenerative Medicine Centers, Academic and Research Institute)

Publication Month: Apr 2021 | Report Code: TIPRE00021550 | No. of Pages: 221 | Category: Biotechnology | Status: Published

The cell therapy bioprocessing is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020. The market is estimated to grow with a CAGR of 13.5% from 2021-2028.

The cell therapy bioprocessing market has been analyzed on the basis of technology, cell type, end user, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company’s competitive landscape analysis to offers insights and in-depth analysis of the cell therapy bioprocessing market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.

Lucrative Regions for Cell Therapy Bioprocessing Market

Lucrative Regions for Cell Therapy Bioprocessing Market

Get more information on this report :


Market Insights

Growing Approvals for Cell Therapies

Cell therapies have shown positive results in treating various chronic diseases including rare genetic disorders by offering regenerative medicines and personalized medicines. Increasing need of treating chronic diseases have pushed the research and development activities resulting in growing cell therapy production and product approvals. Few instances are listed below for the cell therapies approvals that have contributed to the growth of the cell therapy bioprocessing market.

  • In May 2019, the Food and Drug Administration (FDA) approved Zolgensma, manufactured by AveXis, Inc. A subsidiary of Novartis AG. Zolgensa is designed to treat spinal muscular atrophy in children below two years and is given by infusing one-time into the vein.
  • In July 2020, Kite Pharma, Inc., a Subsidiary of Gilead Company, received FDA approval for its Tecartus. Tecartus is (CAR) T cell therapy designed to treat refractory mantle cell lymphoma (MCL) in adults. According to toe Gilead Company, Tecartus is the first approved (CAR) T cell therapy for mantle cell lymphoma, which is expected to be a new frontier in the treatment of mantle cell lymphoma.
  • In February 2021, Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company, received approval for its Breyanzi. Breyanzi is a cell-based gene therapy intended to treat certain types of large B-cell lymphoma in adults. The treatment is given after patient have not responded to minimum two other types of systemic treatment. However, Breyanzi in 2019, faced regulatory setback since its first filing; it is currently under the European Medicines Agency’s review and was validated in July 2020.

Thus, growing product developments have resulted in various product approvals that reflects the increase in cell therapies. Therefore, it is expected that the growing approvals for cell therapies are enormously increasing the cell therapy bioprocessing, which, in turn is likely to drive the market’s growth over the coming years

Technology-Based Insights

The cell therapy bioprocessing market, by technology, is segmented into bioreactor, lyophilization, electro spinning, controlflow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. The Bioreactor segment held the largest share of the market in 2020, whereas the genome editing technology segment is anticipated to register the highest CAGR of 14.5% in the market during the forecast period.

Cell Therapy Bioprocessing Market, by Technology– 2020 and 2028

Cell Therapy Bioprocessing Market, by Technology– 2020 and 2028

Get more information on this report :


Cell Type-Based Insights

The cell therapy bioprocessing market, by cell type, is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, hematopoietic stem cells. The stem cell segment held the largest share of the market in 2020, whereas the same segment is anticipated to register the highest CAGR of 14.0% in the market during the forecast period.

End User-Based Insights

The cell therapy bioprocessing market, by indication, is segmented cardiovascular disease (CVD), oncology, wound healing, orthopedic, and others. The oncology segment held the largest share of the market in 2020, and the orthopedic segment is anticipated to register the highest CAGR of 14.3% in the market during the forecast period.


Strategic Insights

Report Coverage - Cell Therapy Bioprocessing Market
Report CoverageDetails
Market Size Value inUS$ 11,192.50 Million in 2020
Market Size Value byUS$ 30,052.61 Million by 2028
Growth rateCAGR of 13.5% from 2021-2028
Forecast Period2021-2028
Base Year2021
No. of Pages221
No. of Tables111
No. of Charts & Figures87
Historical data availableYes
Segments coveredProduct Type ; Indication ; End user
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

Companies operating in the cell therapy bioprocessing market are adopting organic strategies such as product launches and expansions to expand their footprint and product portfolio worldwide as well as to address the growing demands.

By Technology

  • Bioreactor
  • Lyophilization
  • Electrospinning
  • Controlflow Centrifugation
  • Ultrasonic Lysis
  • Genome Editing Technology
  • Cell Immortalization Technology
  • Viral Vector Technology

By Cell Type

  • Stem Cell
  • Immune Cell
  • Human Embryonic Stem Cell
  • Pluripotent Stem Cell
  • Hematopoetic Stem Cell

By Indication

  • Cardiovascular Disease (CVD)
  • Oncology
  • Wound Healing
  • Orthopedic
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Regenerative Medicine Centers
  • Academic and Research Institute

By Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East and Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Fresenius Kabi AG                                     
  • Asahi Kasei Corporation                          
  • Sartorius AG                                               
  • MERCK KGaA                                             
  • THERMO FISHER SCIENTIFIC INC.           
  • Corning Incorporated                                
  • Cytiva                                                           
  • Lonza                                                           
  • Repligen                                                      
  • Catalent Inc

Frequently Asked Questions

Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
Key factors driving the growth of the market are increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the major factors driving the market growth. However, challenges such as high cost of product, regulatory challenges, and logistics challenges are likely to hinder the growth of the cell therapy bioprocessing market.
The costs of the Cell Therapy Bioprocessing are much higher, and they may cost US$ 50,000–100,000, or more, per cell therapy. The cost may also differ from product to product types.

The List of Companies - Cell Therapy Bioprocessing Market

  1. Fresenius Kabi AG     
  2. Asahi Kasei Corporation         
  3. Sartorius AG              
  4. MERCK KGaA           
  5. THERMO FISHER SCIENTIFIC INC.              
  6. Corning Incorporated             
  7. Cytiva           
  8. Lonza            
  9. Repligen        
  10. Catalent Inc
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the cell therapy bioprocessing market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global cell therapy bioprocessing market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TIPRE00021550
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount